Diagnosis and Management of Bullous Pemphigoid

Diagnostic Criteria and Initial Assessment

The British Journal of Dermatology recommends documenting the distribution and extent of lesions, assessing severity, obtaining a detailed medication history, and evaluating comorbidities in patients with suspected bullous pemphigoid 1, 2
A clinical diagnostic criteria for bullous pemphigoid includes age >70 years, absence of atrophic scars, absence of mucosal involvement, and absence of predominant bullous lesions on neck and head, with a positive direct immunofluorescence (DIF) test 1, 2
The strength of evidence for these diagnostic criteria is high, with a specificity of 95% when three of the four criteria are present with positive DIF 1, 2

The British Journal of Dermatology recommends superpotent topical corticosteroids as first-line treatment for limited disease (<10% body surface area), with a low threshold to escalate to systemic therapy if no improvement is seen within 3-7 days 5, 6
For moderate to extensive disease (>10% body surface area or symptomatic), systemic corticosteroids (prednisone 0.5-0.75 mg/kg/day) are recommended, with a critical dosing consideration to avoid doses >0.75 mg/kg/day due to increased mortality risk in elderly patients 7, 8, 4
The strength of evidence for these treatment recommendations is moderate to high, with a significant reduction in disease severity and improvement in quality of life 5, 6, 7, 8

The British Journal of Dermatology recommends follow-up every 2 weeks during the initial phase (first 3 months) to assess treatment response and adjust therapy, with monitoring for steroid side effects and serial photography to track disease progression 3, 4, 5, 6
During the maintenance phase (after 3 months), monthly follow-up visits are recommended, with gradual dose reduction and tapering of steroids whenever disease has been well controlled for ≥1 month 3, 7, 8
The strength of evidence for these monitoring and follow-up recommendations is moderate, with a significant reduction in disease recurrence and improvement in quality of life 3, 7, 8